{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81"}]}],"title":"Cy8: Rituximab SC much more convenient (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Cy8: Rituximab SC little more convenient (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Cy8: Both formulations equally convenient (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Cy8: Rituximab IV little more convenient (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Cy8: Rituximab IV much more convenient (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88"}]}],"title":"Cy15: Rituximab SC much more convenient (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Cy15: Rituximab SC little more convenient (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Cy15: Both formulations equally convenient (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Cy15: Rituximab IV little more convenient (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Cy15: Rituximab IV much more convenient (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88"}]}],"title":"Cy20: Rituximab SC much more convenient (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Cy20: Rituximab SC little more convenient (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Cy20: Both formulations equally convenient (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Cy20: Rituximab IV little more convenient (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Cy20: Rituximab IV much more convenient (n=126)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"}],"units":"Participants"}],"description":"All investigator physicians and nurses involved in this study were asked to complete question i.e. \"Which formulation of rituximab (SC or IV) do you think is more convenient?\" based on their experience with the rituximab SC and IV formulations across all participants and presented as rituximab SC is much more convenient; rituximab SC is a little more convenient; both formulations are equally convenient; rituximab IV is a little more convenient; and rituximab IV is much more convenient.","groups":[{"description":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP): First cycle rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months. Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP): Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"ITT Population. Here, number of participants analyzed = participants evaluable for the outcome measure. Here \"n\" = number of participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)","title":"Percentage of Responses Who Showed Rituximab SC Formulation Convenient as Compared to Rituximab IV Formulation as Assessed by Physician/Nurse Opinion","type":"SECONDARY","unitOfMeasure":"percentage of responses"}